Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: Two independent characteristics of tamoxifen-resistant breast cancer cells?

Breast Cancer Research and Treatment

Volumn 100, Issue 1, 2006, Pages 1-11

  Scherbakov, Alexander M ^a   Lobanova, Yulia S ^a   Shatskaya, Valentina A ^a   Onopchenko, Oksana V ^a   Gershtein, Elena S ^a   Krasil'nikov, Mikhail A ^a  

^a N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

Author keywords

Apoptosis; Breast cancer; Epidermal growth factor receptor; Estrogen; KDR; MAPK; MCF 7; p53; Tamoxifen resistance; Vascular endothelial growth factor

Indexed keywords

ANTIESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; FC RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; STEROID; TAMOXIFEN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION; SIGNAL TRANSDUCTION;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TAMOXIFEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33749579629     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9075-x     Document Type: Article

References (45)

1. Jordan VC: Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"-20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 36: 267-285, 1995
2. Krasil'nikov MA: [Modern approaches to estrogen-independent growth of breast tumor]. Vopr Onkol 50: 399-405, 2004
3. Osborne CK, Fuqua SA: Mechanisms of tamoxifen resistance. Breast Cancer Res Treat 32: 49-55, 1994
4. Fallowfield LJ: Evolution of breast cancer treatments: current options and quality-of-life considerations. Eur J Oncol Nurs 8(Suppl 2): S75-82, 2004
5. de Cremoux P, Dieras V, Poupon MF, Magdelenat H, Sigal-Zafrani B, Fourquet A, Pierga JY: [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]. Bull Cancer 91: 917-927, 2004
6. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA: Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22: 7316-7339, 2003
7. Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 83: 1477-1482, 1991
8. Takimoto GS, Graham JD, Jackson TA, Tung L, Powell RL, Horwitz LD, Horwitz KB: Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors. J Steroid Biochem Mol Biol 69: 45-50, 1999
9. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995
10. Sun M, Paciga JE, Feldman RI, Yuan Z, Coppola D, Lu YY, Shelley SA, Nicosia SV, Cheng JQ: Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res 61: 5985-5991, 2001
11. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM: Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 97: 9042-9046, 2000
12. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE, Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793-814, 2004
13. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B: Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 229: 161-173, 2005
14. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M: Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278: 30458-30468, 2003
15. Guo P, Fang Q, Tao HQ, Schafer CA, Fenton BM, Ding I, Hu B, Cheng SY: Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo. Cancer Res 63: 4684-4691, 2003
16. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, Mercurio AM: Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 61: 5736-5740, 2001
17. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56: 2013-2016, 1996
18. Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC: Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol 186: 313-318, 1998
19. Gershtein ES, Shcherbakov AM, Alieva SK, Anurova OA, Laktionov KP, Kushlinskii NE: Vascular endothelial growth factor in tumor tissue and blood serum from patients with breast cancer. Bull Exp Biol Med 135: 85-88, 2003
20. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26: 86-91, 1995
21. Kranz A, Mattfeldt T, Waltenberger J: Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84: 293-298, 1999
22. Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Landberg G: Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res Treat 82: 147-154, 2003
23. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996
24. Speirs V, Atkin SL: Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 80: 898-903, 1999
25. Thakker GD, Hajjar DP, Muller WA, Rosengart TK: The role of phosphatidylinositol 3-kinase in vascular endothelial growth factor signaling. J Biol Chem 274: 10002-10007, 1999
26. Yu Y, Hulmes JD, Herley MT, Whitney RG, Crabb JW, Sato JD: Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3′-kinase binding. Biochem J 358: 465-472, 2001
27. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM: Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60: 3183-3190, 2000
28. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN: Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci USA 97: 10972-10977, 2000
29. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M: Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62: 4977-4984, 2002
30. Sonnenschein C, Szelei J, Nye TL, Soto AM: Control of cell proliferation of human breast MCF7 cells; serum and estrogen resistant variants. Oncol Res 6: 373-381, 1994
31. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 93: 1714-1723, 2001
32. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC: Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95: 1586-1597, 2003
33. Song RX, Zhang Z, Mor G, Santen RJ: Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER + breast cancer cells. Apoptosis 10: 667-678, 2005
34. Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res 7: 3156-3165, 2001
35. Yao K, Lee ES, Bentrem DJ, England G, Schafer JI, O'Regan RM, Jordan VC: Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 6: 2028-2036, 2000
36. Berstein LM, Zheng H, Yue W, Wang JP, Lykkesfeldt AE, Naftolin F, Harada H, Shanabrough M, Santen RJ: New approaches to the understanding of tamoxifen action and resistance. Endocr Relat Cancer 10: 267-277, 2003
37. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H: Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for antiestrogen resistance. J Biol Chem 276: 9817-9824, 2001
38. Gershtein ES, Shatskaya VA, Ermilova VD, Kushlinsky NE, Krasil'nikov MA: Phospatidylinositol 3-kinase expression in human breast cancer. Clin Chim Acta 287: 59-67, 1999
39. Krasil'nikov M, Shatskaya V: Signal transducer and activator of transcription-3 and phosphatidylinositol-3 kinase as coordinate regulators of melanoma cell response to glucocorticoid hormones. J Steroid Biochem Mol Biol 82: 369-376, 2002
40. Olea-Serrano N, Devleeschouwer N, Leclercq G, Heuson JC: Assay for estrogen and progesterone receptors of breast cancer cell lines in monolayer culture. Eur J Cancer Clin Oncol 21: 965-973, 1985
41. Moggs JG, Murphy TC, Lim FL, Moore DJ, Stuckey R, Antrobus K, Kimber I, Orphanides G: Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes. J Mol Endocrinol 34: 535-551, 2005
42. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A: High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 67: 111-116, 2001
43. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL: Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer.An updated analysis. Breast Cancer Res Treat 54: 117-122, 1999
44. Katzenellenbogen BS, Kendra KL, Norman MJ, Berthois Y: Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47: 4355-4360, 1987
45. Schlaeppi JM, Eppenberger U, Martiny-Baron G, Kung W: Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates. Clin Chem 42: 1777-1784, 1996